JNJ-40346527

· Johnson & Johnson

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for JNJ-40346527, covering 2013-09-04 to 2024-05-03. Get the full timeline:

Most recent: Clinical Trial Update: Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer [Phase 1]

See pricing